目的 探討益腦寧片聯合阿托伐他汀鈣治療腦動脈硬化癥的臨床療效。方法 選取南開大學附屬醫(yī)院于2015年8月-2016年8月收治的腦動脈硬化癥患者131例，隨機分成對照組（65例）和治療組（66例）。對照組患者口服阿托伐他汀鈣片，10 mg/次，1次/d；治療組在對照組的基礎上口服益腦寧片，4片/次，3次/d。所有患者均經過8周治療。評價兩組患者臨床療效，同時比較治療前后兩組患者血液流變學、疾病相關指標和不良反應情況。結果 對照組和治療組總有效率分別為81.54%、96.97%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者大腦中動脈血流速度顯著升高，頸動脈內膜中膜厚度、斑塊面積和血管搏動指數均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組患者上述疾病相關指標改善情況均要明顯優(yōu)于對照組患者（P<0.05）。治療后，兩組患者的血漿黏度、紅細胞壓積以及紅細胞聚集指數均有所降低（P<0.05）；且治療組患者血液流變學指標降低得更為明顯（P<0.05）。治療期間，對照組不良反應發(fā)生率為18.46%，明顯高于治療組的6.06%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 益腦寧片聯合阿托伐他汀鈣治療腦動脈硬化癥療效顯著，可明顯改善疾病相關指標，安全性高，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacy of Yinaoning Tablets combined with atorvastatin calcium in treatment of cerebral arteriosclerosis. Methods Patients (131 cases) with cerebral arteriosclerosis in Affiliated Hospital of Nankai University from August 2015 to August 2016 were randomly divided into control (65 cases) and treatment (66 cases) groups. Patients in the control group were po administered with Atorvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Yinaoning Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the blood rheology, other disease indexes, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.54% and 96.97%, respectively, and there were differences between two groups (P<0.05). After treatment, the blood flow velocity of middle cerebral artery in two groups was significantly increased, but carotid intima media thickness, plaque area, and vascular pulsatility index were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, plasma viscosity, hematocrit, and red cell assembling indexes in two groups were significantly decreased (P<0.05). And the improvement of the hemorheological indexes in the treatment group were more obvious than those in the control group (P<0.05). During the treatment, the incidence of adverse reactions in the control group was 18.46%, which was significantly higher than 6.06% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Yinaoning Tablets combined with atorvastatin calcium has significant effect in treatment of cerebral arteriosclerosis, can significantly improve disease-related indexes, which has a certain clinical application value.